Wolfgang Link PhD

Wolfgang Link is a CSIC researcher with more than 20 years of experience in basic and translational biomedical research reflected in over 80 articles (40 as senior author, with 5306 citations) published in international peer-reviewed journals, 2 books (Springer, Nature) and 7 book chapters. He holds three patents (one licensed to Sanofi Adventis GMBH), provided numerous invited keynote and plenary presentations at international conferences, and obtained competitive research funds from national and international (US and EU) sources. Dr. Link is a serial entrepreneur (co-founder and CSO of biotech companies; Refoxy Pharmaceuticals, GMBH, Berlin - www.refoxy.com) and served as an advisor for pharmaceutical companies. He also serves as an editorial board member of prestigious, international peer-reviewed journals including Cancers, Frontiers in Oncology, and Frontiers in Cell and Developmental Biology. Dr. Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published papers from the Link lab include national and international collaborators). He has a proven track record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019).

He obtained his Ph.D. degree from the University of Hamburg, followed by a postdoc at CNB (Madrid), before joining the pharma company EleGene AG (Germany) as a senior scientist. In 2001, he moved to Madrid joining the newly-founded CNIO where he was promoted to head the screening group in 2010. In 2012 he accepted a position as assistant professor at the Department of Biomedical Sciences and Medicine (DCBM, University of Algarve, Faro, Portugal) where he was head of the Department of Oncology (CBMR, University of Algarve, Faro, Portugal). His research is focused on understanding and targeting molecular mechanisms underlying anti-cancer therapy resistance and human aging.